Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 3/20 | 0.41 |
| ▸ | MIF | P14174 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.36 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.36 |
| ▸ | SRPK1 | Q96SB4 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10276107 | 0.87 | MAPT (0.32) | MAPTKDM4EALDH1A1 | |
| SCHEMBL10276305 | 0.79 | MAPT (0.44) | TP53MAPTKDM4EALDH1A1HPGD | |
| SCHEMBL10276069 | 0.76 | MAPT (0.49) | TP53MAPTKDM4EALDH1A1HPGD | |
| SCHEMBL10275900 | 0.73 | PGR (0.38) | TP53MAPTKDM4EALDH1A1HPGD | |
| SCHEMBL10276622 | 0.70 | HTT (0.40) | MAPTLMNAALDH1A1 | |
| SCHEMBL10275202 | 0.70 | MAPT (0.39) | TP53MAPTNPC1RAB9A | |
| SCHEMBL10276402 | 0.67 | PGR (0.35) | MAPTKDM4E | |
| SCHEMBL10276024 | 0.66 | MAPT (0.36) | MAPTLMNAKDM4EALDH1A1NPC1 | |
| SCHEMBL10275272 | 0.65 | MEN1 (0.43) | MIFMAPTKDM4EALDH1A1HPGD | |
| SCHEMBL10275560 | 0.65 | PDE4A (0.47) | MIFLMNAKDM4EHPGDNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120178915-A1 | PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF | XU LIFENG (US) | 2012-07-12 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178915-A1 | PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF | TYMP, TYMS, ADORA3 | TP53 2161/4885MIF 4872/4885MAPT 750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.